Rebecca Holmes, NP
Family · Bogalusa, LANPI 1831707470
Payments from drug & device makers
Across 134 payments — averaging $17.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$391
- Lilly USA, LLC$245
- AstraZeneca$220
- UCB, Inc.$184
- Novo Nordisk$173
- Boehringer Ingelheim$157
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,375100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 21 | $391 |
| Lilly USA, LLC | 16 | $245 |
| AstraZeneca | 14 | $220 |
| UCB, Inc. | 8 | $184 |
| Novo Nordisk | 9 | $173 |
| Boehringer Ingelheim | 10 | $157 |
| AbbVie | 7 | $138 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Amgen | 6 | $97 |
| Sumitomo Pharma America, Inc. | 6 | $85 |
| Exact Sciences | 4 | $81 |
| Pfizer | 4 | $77 |
| Teva Pharmaceuticals USA, Inc. | 3 | $63 |
| Verona Pharma, Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Mylan Specialty L.p. | 2 | $29 |
| Johnson & Johnson | 1 | $27 |
| Sanofi | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Dexcom, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Vertex | 1 | $14 |
How this compares
$2,375 in reported general payments places this provider in the 75th percentile of 3,610 family providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $100,590 |
| JardianceEmpagliflozin | 47 | $47,526 |
| FarxigaDapagliflozin Propanediol | 30 | $42,347 |
| EliquisApixaban | 37 | $38,670 |
| TrulicityDulaglutide | 26 | $31,437 |
| RybelsusSemaglutide | 16 | $24,241 |
| MounjaroTirzepatide | 12 | $14,487 |
| EntrestoSacubitril/Valsartan | 16 | $13,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,741 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $11,703 |
| LinzessLinaclotide | 13 | $10,941 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,339 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,690 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $3,493 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $173 | $124,831110 claims |
| AstraZenecaFarxiga, Symbicort | $220 | $48,03743 claims |
| Boehringer IngelheimJardiance | $157 | $47,52647 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $245 | $45,92438 claims |
| PfizerEliquis | $77 | $38,67037 claims |
| MerckJanumet | $16 | $11,70311 claims |
| AbbVieLinzess | $138 | $10,94113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,610 family providers in Louisiana.
Other family in Bogalusa
- Amy SealeBogalusa$50K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.